OncoCyte’s (OCX) “Speculative Buy” Rating Reiterated at Benchmark

OncoCyte (NASDAQ:OCX)‘s stock had its “speculative buy” rating reiterated by equities research analysts at Benchmark in a research report issued on Monday, Benzinga reports. They presently have a $5.00 price target on the stock. Benchmark’s price target suggests a potential upside of 81.82% from the company’s current price.

Separately, StockNews.com started coverage on OncoCyte in a research note on Friday, April 12th. They set a “sell” rating for the company.

OncoCyte Stock Up 8.7 %

OCX stock opened at $2.75 on Monday. The business has a 50-day simple moving average of $2.96 and a 200 day simple moving average of $3.06. OncoCyte has a 52 week low of $2.08 and a 52 week high of $6.80.

Insiders Place Their Bets

In other news, major shareholder Broadwood Partners, L.P. acquired 2,420,000 shares of the stock in a transaction dated Thursday, April 11th. The stock was bought at an average price of $2.92 per share, with a total value of $7,066,400.00. Following the completion of the purchase, the insider now directly owns 4,929,066 shares of the company’s stock, valued at approximately $14,392,872.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Andrew Arno acquired 33,898 shares of the stock in a transaction dated Thursday, April 11th. The stock was bought at an average price of $2.95 per share, with a total value of $99,999.10. Following the completion of the purchase, the director now directly owns 69,054 shares of the company’s stock, valued at approximately $203,709.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Broadwood Partners, L.P. acquired 2,420,000 shares of the stock in a transaction dated Thursday, April 11th. The stock was purchased at an average cost of $2.92 per share, with a total value of $7,066,400.00. Following the purchase, the insider now directly owns 4,929,066 shares of the company’s stock, valued at $14,392,872.72. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 2,457,288 shares of company stock valued at $7,176,400. 1.94% of the stock is currently owned by corporate insiders.

Institutional Trading of OncoCyte

Institutional investors have recently added to or reduced their stakes in the stock. Raymond James Financial Services Advisors Inc. bought a new stake in OncoCyte in the first quarter valued at approximately $25,000. DCF Advisers LLC boosted its holdings in OncoCyte by 107.0% in the first quarter. DCF Advisers LLC now owns 25,149 shares of the company’s stock valued at $37,000 after acquiring an additional 13,000 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in OncoCyte in the second quarter valued at approximately $25,000. Balyasny Asset Management LLC boosted its holdings in OncoCyte by 389.9% in the third quarter. Balyasny Asset Management LLC now owns 52,887 shares of the company’s stock valued at $39,000 after acquiring an additional 42,091 shares during the last quarter. Finally, LPL Financial LLC boosted its holdings in OncoCyte by 58.1% in the second quarter. LPL Financial LLC now owns 108,816 shares of the company’s stock valued at $98,000 after acquiring an additional 40,000 shares during the last quarter. 55.35% of the stock is currently owned by institutional investors.

OncoCyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.